Ramazan ve Diyabet
Özet
Ramazan ayında oruç tutmak, şafaktan gün batımına kadar yeme ve içmeden uzak durmayı gerektiren sirkadiyen bir ritim değişikliğidir. Diyabetli bireyler için bu uzun süreli açlık dönümü; hipoglisemi, hiperglisemi, diyabetik ketoasidoz ve dehidratasyon gibi ciddi metabolik riskleri beraberinde getirir. Sağlıklı insanlarda açlık sırasında insülin baskılanıp glukagon devreye girerek şeker dengelenirken, diyabet hastalarında bu homeostaz mekanizması bozulur. Bu nedenle, oruç tutmak isteyen diyabetlilerin Ramazan'dan en az 6-12 hafta önce kapsamlı bir tıbbi değerlendirmeden geçmesi şarttır. Hastalar taşıdıkları risk düzeyine göre çok yüksek, yüksek, orta ve düşük risk gruplarına sınıflandırılmalıdır. Özellikle son üç ayda şiddetli hipoglisemi öyküsü olanlar, gebeler ve kontrolsüz tip 1 diyabetliler çok yüksek risk grubunda yer alır ve oruç tutmaları önerilmez. Ramazan boyunca oruç tutmayı planlayan bireylerde antidiyabetik ilaçların ve insülin rejimlerinin dozajları ile zamanlamaları iftar ve sahur düzenine göre yeniden yapılandırılmalıdır. Metformin gibi glukoza bağımlı çalışan ilaçlar genellikle doz değişikliği gerektirmezken, sülfonilüreler ve insülin kullanan hastaların dozlarında hipoglisemi riskini önlemek adına önemli ayarlamalar yapılmalı ve kan şekeri takibi sıklaştırılmalıdır.
Fasting during Ramadan represents a major shift in circadian rhythm, requiring complete abstinence from food and fluids from dawn to sunset. For individuals with diabetes, this prolonged fasting period introduces significant metabolic risks, including hypoglycemia, hyperglycemia, diabetic ketoacidosis, and dehydration. While healthy individuals maintain glucose homeostasis during fasting through insulin suppression and glucagon secretion, this regulatory counter-mechanism is altered in patients with diabetes. Consequently, individuals with diabetes who wish to fast should undergo a comprehensive pre-Ramadan assessment at least 6–12 weeks prior to the holy month. Patients are categorized into very high, high, moderate, and low risk groups based on their health status. Pregnant women, patients with poorly controlled type 1 diabetes, and those with a history of severe hypoglycemia within the preceding three months fall into the very high risk category and are strongly advised against fasting. For those who proceed, medication and insulin regimens must be adjusted to align with the altered eating patterns of Iftar and Suhoor. Medications like metformin generally require no dose modification, whereas sulfonylureas and insulin doses must be carefully reduced to prevent severe hypoglycemia through structured self-monitoring.
Referanslar
Babineaux SM, Toaima D, Boye KS, et al. Multi-country retrospective observational study of the management and outcomes of patients with Type 2 diabetes during Ramadan in 2010 (CREED). Diabetic medicine : a journal of the British Diabetic Association. 2015;32(6): 819–828. https://doi.org/10.1111/dme.12685
Bajaj HS, Abouhassan T, Ahsan MR, et al. Diabetes Canada Position Statement for People With Types 1 and 2 Diabetes Who Fast During Ramadan. Canadian journal of diabetes. 2019;43(1), 3–12. https://doi.org/10.1016/j.jcjd.2018.04.007
Salti I, Bénard E, Detournay B, et al. A population-based study of diabetes and its characteristics during the fasting month of ramadan in 13 countries: Results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes care. 2004;27(10): 2306–2311.
Hassanein M, Afandi B, Yakoob Ahmedani M, et al. Diabetes and Ramadan: Practical guidelines 2021. Diabetes research and clinical practice. 2022;185, 109185. https://doi.org/10.1016/j.diabres.2021.109185
Anton SD, Moehl K, Donahoo WT, et al. Flipping the metabolic switch: understanding and applying the health benefits of fasting. Obesity (Silver Spring) 2018;26(2): 254-268. doı:10.1002/oby.22065
Lessan N, Ali T. Energy Metabolism and Intermittent Fasting: The Ramadan Perspective. Nutrients. 2019;11(5):1192. Published 2019 May 27. doi:10.3390/nu11051192
Lessan N, Hannoun Z, Hasan H, et al. Glucose excursions and glycaemic control during Ramadan fasting in diabetic patients: insights from continuous glucose monitoring (CGM). Diabetes & Metabolism. 2015;41(1): 28-36.
Lessan N, Saadane I, Alkaf B, et al. The effects of Ramadan fasting on activity and energy expenditure. The American journal of clinical nutrition. 2018;107(1), 54–61. https://doi.org/10.1093/ajcn/nqx016
Ajabnoor GM, Bahijri S, Shaik NA, et al. Ramadan fasting in Saudi Arabia is associated with altered expression of CLOCK, DUSP and IL-1alpha genes, as well as changes in cardiometabolic risk factors. PloS one. 2017;12(4): e0174342.
Ahmed SH, Chowdhury TA, Hussain S, et al. Ramadan and Diabetes: A Narrative Review and Practice Update [published online ahead of print, 2020 Sep 9]. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2020;1-44. doi:10.1007/s13300-020-00886-y
Chowdhury A, Khan H, Shawarna SL, et al. A survey of patients with type 2 diabetes and fasting outcomes during Ramadan 2016 in London: the East London Diabetes in Ramadan Survey. The British Journal of Diabetes. 2017;17(4):149–151.
Tan C, Yong AML, Haji Mohamad MA, et al. Fasting in Ramadan of Muslim patients with diabetes Mellitus, and knowledge and practice in relation to diabetes control in Brunei. Diabetes research and clinical practice. 2018;144: 171-176. doi:10.1016/j.diabres.2018.09.004
Ibrahim M, Davies MJ, Ahmad E, et al. Recommendations for management of diabetes during Ramadan: update 2020, applying the principles of the ADA/EASD consensus. BMJ Open Diabetes Research Care. 2020;8(1):e001248. doi:10.1136/bmjdrc-2020-001248
Jabbar A, Hassanein M, Beshyah SA, et al. CREED study: Hypoglycaemia during Ramadan in individuals with Type 2 diabetes mellitus from three continents. Diabetes research and clinical practice. 2017;132: 19-26.
Tourkmani AM, Abdelhay O, Alharbi TJ, et al. Impact of Ramadan-focused diabetes education on hypoglycemia risk and metabolic control for patients with type 2 diabetes mellitus: A systematic review. International journal of clinical practice. 2021;75(3):e13817. doi:10.1111/ijcp.13817
Ahmedani MY, Haque MS, Basit A, et al. Ramadan Prospective Diabetes Study: the role of drug dosage and timing alteration, active glucose monitoring and patient education. Diabetic medicine : a journal of the British Diabetic Association. 2012;29(6):709-715. doi:10.1111/j.1464-5491.2011.03563.x
Shadman Z, Akhoundan M, Poorsoltan N, et al. Nutritional Education Needs in Relation to Ramadan Fasting and Its Complications in Tehran, Iran. Iranian Red Crescent Medical Journal. 2016;18(8):e26130. Published 2016 Jun 8. doi:10.5812/ircmj.26130
Aldawi N, Darwiche G, Abusnana S, et al. Initial increase in glucose variability during Ramadan fasting in non-insulintreated patients with diabetes type 2 using continuous glucose monitoring. Libyan Journal of Medicine. 2019;14(1): 1-5.
Hassanein M, Al Sifri S, Shaikh S, et al. DIA-RAMADAN study investigators A real-world study in patients with type 2 diabetes mellitus treated with gliclazide modified-release during fasting: DIA-RAMADAN. Diabetes Research and Clinical Practice. 2020;163: 108154.
Bashier A, Khalifa AA, Abdelgadir EI, et al. Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2-I) During the Month of Ramadan in Muslim Patients with Type 2 Diabetes. Oman medical journal, 2018;33(2):104-110. doi:10.5001/omj.2018.21
Shao Y, Lim GJ, Chua CL, et al. The effect of Ramadan fasting and continuing sodium-glucose co-transporter-2 (SGLT2) inhibitor use on ketonemia, blood pressure and renal function in Muslim patients with type 2 diabetes. Diabetes research and clinical practice. 2018;142: 85-91.
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (London, England). 2006;368(9548):1696-1705. doi:10.1016/S0140-6736(06)69705-5
Hassanein M, Hanif W, Malik W, et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Current medical research and opinion, 2011;27(7): 1367-1374.
Al-Arouj M, Hassoun AAK, Medlej R, et al. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the virtue study. International journal of clinical practice. 2013;67: 957–963. doi:10.1111/ijcp.12243
Hassanein M, Abdallah K, Schweizer A, A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Vascular health and risk management 2014;10: 319–326. doi:10.2147/VHRM.S64038
Khunti K, Chatterjee S, Gerstein HC, et al. Do sulphonylureas still have a place in clinical practice?. The Lancet Diabetes & Endocrinology. 2018;6(10):821-832. doi:10.1016/S2213-8587(18)30025-1
Zargar AH, Siraj M, Jawa AA, et al. Maintenance of glycaemic control with the evening administration of a long acting sulphonylurea in male type 2 diabetic patients undertaking the Ramadan fast. International journal of clinical practice. 2010;64(8):1090-1094. doi:10.1111/j.1742-1241.2009.02262.x
Anwar A, Azmi K, Hamidon B, et al. An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan. The Medical journal of Malaysia. 2006;61: 28–35.
Van de Laar FA, Lucassen PL, Akkermans RP, et. Alpha-Glucosidase inhibitors for type 2 diabetes mellitus. Cochrane database of systematic reviews 2. 2005;18:CD003639
Marso SP, McGuire DK, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. The New England journal of medicine. 2017;377(8):723-732. doi:10.1056/NEJMoa1615692
Rosenstock J, Jelaska A, Zeller C, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes, obesity & metabolism 2015;17: 936–948 https://doi.org/doi:10.1111/dom.12503
Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with Empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 2014;37: 1815-1823 https://doi.org/doi:10.2337/dc13-3055
Ali S, Davies MJ, Brady EM, et al. Guidelines for managing diabetes in Ramadan. Diabetic Medicine 2016;33: 1315–1329.doi:10.1111/dme.13080
